Direct inotropic effects of exogenous and endogenous urotensin-II: Divergent actions in failing and nonfailing human myocardium

Circulation: Heart Failure

Volumn 2, Issue 1, 2009, Pages 39-46

  Quaile, Michael P ^a,c   Kubo, Hajime ^a   Kimbrough, Carie L ^b   Douglas, Stephen A ^b   Margulies, Kenneth B ^c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Calcium; Contractility; Myocardial contraction; Pharmacology; Sarcoplasmic reticulum

Indexed keywords

GSK 248451A; PHOSPHOLAMBAN; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR ANTAGONIST; VASOCONSTRICTOR AGENT;

ADULT; ARTICLE; CALCIUM CELL LEVEL; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; FEMALE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INOTROPISM; MALE; MUSCLE CELL; PHOSPHORYLATION; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM;

ADULT; BLOTTING, WESTERN; ENZYME INHIBITORS; HEART FAILURE; HUMANS; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; SIGNAL TRANSDUCTION; SODIUM; SODIUM-HYDROGEN ANTIPORTER; UROTENSINS;

EID: 77953669523     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.107.748343     Document Type: Article

References (29)

1. Francis GS. Pathophysiology of chronic heart failure. Am J Med. 2001; 110:37S- 46S.
2. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999; 341:577-585.
3. Lapp H, Boerrigter G, Costello-Boerrigter LC, Jaekel K, Scheffold T, Krakau I, Schramm M, Guelker H, Stasch JP. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol. 2004; 94:93-97.
4. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation. 2002; 106:2877-2880.
5. Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P, Molenaar P. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol. 2003; 285: H1576-H1581.
6. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2002; 359: 1990-1997.
7. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet. 2002; 360:545-546.
8. Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N, Douglas SA. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol. 2004; 370:238 -250.
9. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res. 2003; 93: 246-253.
10. Zhou P, Wu SY, Yu CF, Wang H, Tang CS, Lin L, Yuan WJ. Effects of urotensin II on isolated rat hearts under normal perfusion and ischemia reperfusion. Sheng Li Xue Bao. 2003; 55:442- 448.
11. Russell FD, Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc Res. 2004; 63:673- 681.
12. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol. 2001; 132:5-9.
13. Penna C, Rastaldo R, Mancardi D, Cappello S, Pagliaro P, Westerhof N, Losano G. Effect of endothelins on the cardiovascular system. J Cardiovasc Med (Hagerstown). 2006; 7:645- 652.
14. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998; 97:2316 -2322.
15. Rossman EI, Petre RE, Chaudhary KW, Piacentino V III, Janssen PM, Gaughan JP, Houser SR, Margulies KB. Abnormal frequency-dependent responses represent the pathophysiologic signature of contractile failure in human myocardium. J Mol Cell Cardiol. 2004; 36:33- 42.
16. Janssen PM, Lehnart SE, Prestle J, Lynker JC, Salfeld P, Just H, Hasenfuss G. The trabecula culture system: a novel technique to study contractile parameters over a multiday time period. Am J Physiol. 1998; 274:H1481-H1488.
17. Behm DJ, Stankus G, Doe CP, Willette RN, Sarau HM, Foley JJ, Schmidt DB, Nuthulaganti P, Fornwald JA, Ames RS, Lambert DG, Calo G, Camarda V, Aiyar NV, Douglas SA. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems. Br J Pharmacol. 2006; 148:173-190.
18. Quaile MP, Rossman EI, Berretta RM, Bratinov G, Kubo H, Houser SR, Margulies KB. Reduced sarcoplasmic reticulum Ca(2+) load mediates impaired contractile reserve in right ventricular pressure overload. J Mol Cell Cardiol. 2007; 43:552-563.
19. Petre RE, Quaile MP, Rossman EI, Ratcliffe SJ, Bailey BA, Houser SR, Margulies KB. Sex-based differences in myocardial contractile reserve. Am J Physiol Regul Integr Comp Physiol. 2007; 292:R810-R818.
20. Mattiello JA, Margulies KB, Jeevanandam V, Houser SR. Contribution of reverse-mode sodium-calcium exchange to contractions in failing human left ventricular myocytes. Cardiovasc Res. 1998; 37:424-431.
21. Kubo H, Margulies KB, Piacentino V III, Gaughan JP, Houser SR. Patients with end-stage congestive heart failure treated with betaadrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation. 2001; 104:1012-1018.
22. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, Coats AJ, Anker SD, Gatzoulis MA. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002; 106:92-99.
23. Davila DF, Nunez TJ, Odreman R, de Davila, CA. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int J Cardiol. 2005; 101:343-346.
24. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. 2005; 95:8B-13B.
25. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999; 401:282-286.
26. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 2000; 131: 1262-1274.
27. Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation. 2004; 109:1212-1214.
28. Bousette N, Hu F, Ohlstein EH, Dhanak D, Douglas SA, Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol. 2006; 41: 285-295.
29. Li J, Wang J, Russell FD, Molenaar P. Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II. Br J Pharmacol. 2005; 145:432- 440.